Intel Corporation

NASDAQ Global Select
Slightly Bullish +25

What Is The Case For Waiting On Intel Stock?

📈 Intel stock is up about 334% over the past year against 17.1% for the S&P 500.

💰 The company posted a net loss of $11.3 billion over the last twelve months despite recovering operating profit.

🏭 Intel Foundry posted an operating loss of $2.1 billion in the second quarter of 2026.

📊 New chips such as Panther Lake still earn below the company's average margin.

🚀 Intel beat its own revenue forecast by $1.8 billion in the second quarter of 2026.

📉 Demand for products continues to outpace Intel's growing supply capacity.

📅 Management guided third-quarter revenue between $15.8 billion and $16.8 billion.

📈 Analyst consensus for Q3 is about $16.7 billion, near the top of the guide.

📉 Intel stock fell 8.5% over two trading days after the July 23, 2026 report.

🔮 The company is expected to report third-quarter figures on or around October 22, 2026.

💹 Management forecasts an adjusted gross margin of 42% for the third quarter.

⚠️ Waiting on Intel could be costly if profits catch up with the current high price.

Bullish Signals
  • Intel stock is up about 334% over the past year, significantly outperforming the S&P 500.
  • Intel beat its own revenue forecast by $1.8 billion in the second quarter of 2026.
  • Management stated that demand for its products continues to outpace its growing supply capacity.
  • The company successfully recovered from an operating loss, with margins at 7.6% over the last twelve months.
Risk Factors
  • Intel still posted a net loss of $11.3 billion over the last twelve months despite recovering operating profit.
  • Intel Foundry posted an operating loss of $2.1 billion in the second quarter of 2026.
  • New chips such as Panther Lake still earn below the company's average margin.
  • The stock trades at 30.4 times operating cash flow, significantly higher than the S&P 500's 14.6x multiple.
  • Intel stock fell 8.5% over two trading days following the July 23, 2026 report despite beating sales forecasts.
Full Analysis
Intel (INTC) stock has surged approximately 334% over the past year, significantly outperforming the S&P 500's 17.1% gain. The current valuation of roughly $127.39 per share relies heavily on the expectation that operating profits will continue to climb and that sales will consistently beat the company's own forecasts. However, despite this recovery in operating profit from a previous loss, Intel still reported a net loss of $11.3 billion over the last twelve months. The stock currently trades at 30.4 times its operating cash flow and 8.0 times sales, multiples that are high compared to historical ranges and the broader market. A significant drag on profitability remains with Intel Foundry, which posted an operating loss of $2.1 billion in the second quarter of 2026. Management notes that new chips like Panther Lake are still early in their life cycle and earn below the company's average margin, meaning today's price depends mostly on sales volume rather than robust margins. In the second quarter of 2026, Intel beat its own revenue forecast by $1.8 billion, with demand continuing to outpace supply capacity. For the third quarter, management guided revenue between $15.8 billion and $16.8 billion, while analyst consensus sits near the top of that range at approximately $16.7 billion. The stock has shown high volatility following recent reports, falling 8.5% after a beat in July but rising 27% after an April report, indicating that future performance will heavily influence investor sentiment. Analysts suggest that waiting to buy Intel could be costly if profits catch up with the current price, which is currently supported more by sales than earnings. Management forecasts an adjusted gross margin of 42% for the third quarter at the midpoint of revenue guidance. If revenue hits the high end of $16.8 billion and margins clear that 42% forecast, both sales and profits would run ahead of plan, making a wait a poor choice. Conversely, if margins fall short, the current price may be premature.